Targeted agents: Review of toxicity in the elderly metastatic colorectal cancer patients

Targeted Oncology

Volumn 6, Issue 4, 2011, Pages 245-251

  Kyriakou, Flora ^a   Kountourakis, Panteleimon ^a   Papamichael, Demetris ^a  

^a Bank of Cyprus Group Oncology Centre   (Cyprus)

Author keywords

Colorectal cancer; Efficacy; Elderly patients; Targeted therapy; Toxicity

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ABDOMINAL PAIN; ACNE; AGE; AGED; ANOREXIA; ASTHENIA; BLEEDING; BLOOD TOXICITY; CANCER SURVIVAL; COLORECTAL CANCER; CONFUSION; DERMATITIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ELDERLY CARE; ERYTHEMA; FATIGUE; FOLLICULITIS; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GERIATRIC PATIENT; HIGH RISK POPULATION; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; INFECTION; MACULOPAPULAR RASH; METASTASIS; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PARONYCHIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; RASH; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SKIN MANIFESTATION; SKIN TOXICITY; VENOUS THROMBOEMBOLISM; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS;

EID: 84856026641     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-011-0198-1     Document Type: Review

References (40)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300
2. Aapro MS, Kohne CH, Cohen HJ, Extermann M (2005) Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist 10:198-204 (Pubitemid 40463157)
3. Berrino F, Capoccaccia R, Esteve J, Gatta G (1999) Survival of cancer patients in Europe: the EUROCARE-2 study. IARC Sci Publ 151:1-572
4. Hutchins LF, Unger JM, Crowley JJ et al (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 30:2061-2067 (Pubitemid 30035956)
5. Lewis JH, Kilgore ML, Goldman DP et al (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21(7):1383-1389 (Pubitemid 46606420)
6. Folprecht G, Cunningham D, Ross P et al (2004) Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 15(9):1330-1338 (Pubitemid 39302467)
7. Popescu RA, Norman A, Ross PJ et al (1999) Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17(8):2412-2418 (Pubitemid 29368240)
8. Folprecht G, Seymour MT, Saltz L et al (2008) Irinotecan/ fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 26 (9):1443-1451
9. Goldberg RM, Tabah-Fisch I, Bleiberg H et al (2006) Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/ leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24(25):4085-4091 (Pubitemid 46622283)
10. Figer A, Perez-Staub N, Carola E et al (2007) FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer 110(12):2666-2671 (Pubitemid 350250335)
11. François E, Berdah JF, Chamorey E et al (2008) Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. Cancer Chemother Pharmacol 62:931-936
12. Aparicio T, Desramé J, Lecomte T et al (2003) Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer 89:1439-1444 (Pubitemid 37386597)
13. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 351:337-345 (Pubitemid 38944402)
14. Jonker DJ, O'Callaghan CJ, Karapetis CS et al (2009) Cetuximab for the treatment of colorectal cancer. N Engl J Med 360 (14):1408-1417
15. Asmis TR, Powell E, Karapetis CS et al (2011) Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)-results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Ann Oncol 22(1):118-126
16. Bouchahda M, Macarulla T, Spano JP et al (2008) Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit Rev Oncol Hematol 67(3):255-262
17. Fornaro L, Baldi GG, Masi G et al (2011) Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status. Crit Rev Oncol Hematol 78 (3):243-251
18. Sastre J, Aranda E, Grávalos C et al (2011) First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol 77 (1):78-84
19. Van Cutsem E, Köhne C-H, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. NEJM 360:1408-1417
20. Su X, Lacouture ME, Jia Y, Wu S (2009) Risk of high-grade skin rash in cancer patients treated with cetuximab - an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology 77(2):124-133
21. Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26(14):2311-2319
22. Siena S, Glynne-Jones R, Adenis A et al (2010) Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. Cancer 116(7):1827-1837
23. Tejpar S, Piessevaux H, Claes K et al (2007) Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 8 (5):387-394 (Pubitemid 46621761)
24. Schrag D, Chung KY, Flombaum C, Saltz L (2005) Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 97 (16):1221-1224 (Pubitemid 41258228)
25. Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapyrefractory metastatic colorectal cancer. J Clin Oncol 25(13):1658-1664 (Pubitemid 46797944)
26. Van Cutsem E, Siena S, Humblet Y et al (2008) An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 19(1):92-98
27. Douillard J-Y, Siena S, Cassidy J et al (2010) Randomized, phase III trial of panitumumab with infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 31:4697-4705
28. Peeters M, Price TJ, Cervantes A et al (2010) Randomized phase III study of panitumumab with Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) compared with FOLFIRI alone as secondline treatment in patients with metastatic colorectal cancer. J Clin Oncol 31:4706-4713
29. Heun J, Holen K (2007) Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clin Colorectal Cancer 6 (7):529-531 (Pubitemid 46918159)
30. Cartwright TH, Genther R (2008) Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer. Clin Colorectal Cancer 7(3):202-203 (Pubitemid 351758151)
31. Kabbinavar FF, Hurwitz HI, Yi J et al (2009) Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 27 (2):199-205
32. Cassidy J, Saltz LB, Giantonio BJ et al (2010) Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol 136(5):737-743
33. Kozloff M, Yood MU, Berlin J et al (2009) Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 14(9):862-870
34. Kozloff MF, Berlin J, Flynn PJ et al (2010) Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology 78(5-6):329-339
35. Van Cutsem E, Rivera F, Berry S et al (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20(11):1842-1847
36. Kubala E, Bartos J, Petruzelka LB et al (2010) Safety and effectiveness of bevacizumab (bev) in combination with chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): Results from a large Czech observational registry (CSTP). Proc Am Soc Clin Oncol Gastrointest Cancer Symp 2010, Abstr 467
37. Nalluri SR, Chu D, Keresztes R et al (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300(19):2277-2285
38. Hurwitz HI, Saltz LB, Van Cutsem E et al (2011) Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 13:1757-1764
39. Scappaticci FA, Skillings JR, Holden SN et al (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99(16):1232-1239 (Pubitemid 47299901)
40. Ranpura V, Hapani S, Chuang J, Wu S (2010) Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 49(3):287-297